Tags

Type your tag names separated by a space and hit enter

CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
Retina. 2018 09; 38(9):1801-1808.R

Abstract

PURPOSE

The aim of this study was to investigate the changes in plasma vascular endothelial growth factor (VEGF) level depending on the severity of diabetic retinopathy (DR) or diabetic macular edema (DME) and after intravitreal injection of bevacizumab, aflibercept, or ranibizumab for treatment of DME.

METHODS

Plasma VEGF level was evaluated in 72 patients with DR and changes were measured in 42 patients with DME receiving intravitreal injections of bevacizumab, aflibercept, or ranibizumab at the initial injection.

RESULTS

There were no correlations between plasma VEGF level and the severity of DME or DR. Baseline plasma VEGF level (51.9 pg/mL) was significantly reduced using bevacizumab to 11.9 pg/mL after 1 week and 24.1 pg/mL after 4 weeks (P = 0.0130 and 0.0201, respectively). In aflibercept-treated eyes, plasma VEGF decreased from 52.2 pg/mL to 7.8 pg/mL and 12.6 pg/mL, respectively, at the same time points (both P < 0.001). No such reductions were observed in patients receiving ranibizumab.

CONCLUSION

Baseline plasma VEGF level showed no correlations with DR or DME severity, whereas intravitreal injection of bevacizumab or aflibercept significantly reduced plasma VEGF for up to 4 weeks and ranibizumab produced no such effects. Changes in plasma VEGF level seemed not to be critical in progression or treatment of DME and DR.

Authors+Show Affiliations

Department of Ophthalmology, School of Medicine, Shinshu University, Matsumoto, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

29280940

Citation

Hirano, Takao, et al. "CHANGES in PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION of BEVACIZUMAB, AFLIBERCEPT, or RANIBIZUMAB for DIABETIC MACULAR EDEMA." Retina (Philadelphia, Pa.), vol. 38, no. 9, 2018, pp. 1801-1808.
Hirano T, Toriyama Y, Iesato Y, et al. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA. Retina. 2018;38(9):1801-1808.
Hirano, T., Toriyama, Y., Iesato, Y., Imai, A., & Murata, T. (2018). CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA. Retina (Philadelphia, Pa.), 38(9), 1801-1808. https://doi.org/10.1097/IAE.0000000000002004
Hirano T, et al. CHANGES in PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION of BEVACIZUMAB, AFLIBERCEPT, or RANIBIZUMAB for DIABETIC MACULAR EDEMA. Retina. 2018;38(9):1801-1808. PubMed PMID: 29280940.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA. AU - Hirano,Takao, AU - Toriyama,Yuichi, AU - Iesato,Yasuhiro, AU - Imai,Akira, AU - Murata,Toshinori, PY - 2017/12/28/pubmed PY - 2018/9/6/medline PY - 2017/12/28/entrez SP - 1801 EP - 1808 JF - Retina (Philadelphia, Pa.) JO - Retina VL - 38 IS - 9 N2 - PURPOSE: The aim of this study was to investigate the changes in plasma vascular endothelial growth factor (VEGF) level depending on the severity of diabetic retinopathy (DR) or diabetic macular edema (DME) and after intravitreal injection of bevacizumab, aflibercept, or ranibizumab for treatment of DME. METHODS: Plasma VEGF level was evaluated in 72 patients with DR and changes were measured in 42 patients with DME receiving intravitreal injections of bevacizumab, aflibercept, or ranibizumab at the initial injection. RESULTS: There were no correlations between plasma VEGF level and the severity of DME or DR. Baseline plasma VEGF level (51.9 pg/mL) was significantly reduced using bevacizumab to 11.9 pg/mL after 1 week and 24.1 pg/mL after 4 weeks (P = 0.0130 and 0.0201, respectively). In aflibercept-treated eyes, plasma VEGF decreased from 52.2 pg/mL to 7.8 pg/mL and 12.6 pg/mL, respectively, at the same time points (both P < 0.001). No such reductions were observed in patients receiving ranibizumab. CONCLUSION: Baseline plasma VEGF level showed no correlations with DR or DME severity, whereas intravitreal injection of bevacizumab or aflibercept significantly reduced plasma VEGF for up to 4 weeks and ranibizumab produced no such effects. Changes in plasma VEGF level seemed not to be critical in progression or treatment of DME and DR. SN - 1539-2864 UR - https://www.unboundmedicine.com/medline/citation/29280940/CHANGES_IN_PLASMA_VASCULAR_ENDOTHELIAL_GROWTH_FACTOR_LEVEL_AFTER_INTRAVITREAL_INJECTION_OF_BEVACIZUMAB_AFLIBERCEPT_OR_RANIBIZUMAB_FOR_DIABETIC_MACULAR_EDEMA_ L2 - https://doi.org/10.1097/IAE.0000000000002004 DB - PRIME DP - Unbound Medicine ER -